<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01642472</url>
  </required_header>
  <id_info>
    <org_study_id>PGL11-024</org_study_id>
    <nct_id>NCT01642472</nct_id>
  </id_info>
  <brief_title>PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata</brief_title>
  <acronym>PEARLext2</acronym>
  <official_title>A Phase III, Multicentre, Extension Study Investigating the Efficacy and Safety of Repeated Intermittent 3-month Courses of Open-label Administration of Ulipristal Acetate, in Subjects With Symptomatic Uterine Myomas and Heavy Uterine Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PregLem SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PregLem SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multicentre, long-term open-label extension of the phase III study:
      Pearl IIIextension (PGL09-027). During Pearl III (PGL09-026) and subsequent Pearl III
      extension (PGL09-027), patients have been exposed to a total of 4 cycles of daily 3month
      open-label treatment with ulipristal acetate 10mg before entering the proposed study Pearl
      extension 2 (PGL11-024).

      This proposed study consists of 4 further consecutive courses of 3 months (84 days) open
      label ulipristal acetate 10mg once daily treatment each separated by a drug free period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myoma symptom control assessed with a Global Study Treatment Satisfaction Questionnaire</measure>
    <time_frame>9 months</time_frame>
    <description>Average score of the first 3 questions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myoma symptom control assessed with a Global Study Treatment Satisfaction Questionnaire</measure>
    <time_frame>18 months</time_frame>
    <description>Average score of the first 3 questions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>Ulipristal Acetate (PGL4001) 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulipristal Acetate (PGL4001)10mg daily administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulipristal Acetate - open label</intervention_name>
    <description>Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.</description>
    <arm_group_label>Ulipristal Acetate (PGL4001) 10mg</arm_group_label>
    <other_name>PGL4001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject completed visit F - Follow-up of Pearl III extension study (PGL09-027) -
             without significant deviations.

          -  Females of childbearing potential are advised to practice a non-hormonal method of
             contraception.

        Exclusion Criteria:

          -  Subject has a history of uterus surgery (e.g. hysterectomy, myomectomy) or uterine
             artery embolization in Pearl III extension (PGL09-027) or afterwards that would
             interfere with the study assessments.

          -  Subject has taken or is likely to require treatment during the study with drugs that
             are not permitted by the study protocol.

          -  Subject is lactating, has a positive pregnancy test at study start or is planning a
             pregnancy during the course of the study.

          -  Subject has abnormal baseline findings, any other medical condition(s) or laboratory
             finding that, in the opinion of the investigator, might jeopardise the subject's
             safety or interfere with study evaluations.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elke Bestel, Dr</last_name>
    <role>Study Director</role>
    <affiliation>PregLem SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc, Gynécologie-Obstétrique,</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de la Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires UCL de Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Klinika Polozniczo-Ginekologiczna</name>
      <address>
        <city>Bialystok</city>
        <zip>15-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INVICTA Sp. Z o.o.</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-895</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Katowice</city>
        <zip>40-724</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatny Gabinet Lekarski Ginekologia I Poloznictwo Ultrasonografia</name>
      <address>
        <city>Lodz</city>
        <zip>90-602</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Gabinet Ginekologiczno-Polozniczy</name>
      <address>
        <city>Lublin</city>
        <zip>20-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski Specjalistyczny &quot;Sonus&quot;</name>
      <address>
        <city>Warszawa</city>
        <zip>02-066</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA w Warszawie, Klinika Poloznictwa, Chorob Kobiecych i Ginekologii Onkologicznej</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu, I Katedra i Klinika Ginekologii i Położnictwa</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-369</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall Hebrón (Gynecology department) Edificio Maternal</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Ginecologica CEOGA</name>
      <address>
        <city>Lugo</city>
        <zip>27002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOSPITAL Universitario 12 de Octubre y Fundación de Investigación Biomédica Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2012</study_first_posted>
  <last_update_submitted>January 7, 2016</last_update_submitted>
  <last_update_submitted_qc>January 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

